Tytuł pozycji:

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Szczegóły
Pełny tekst

Tytuł:: The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
Autorzy:: Fruchart, Jean-Charles
Santos, Raul D.
Aguilar-Salinas, CarlosAff3, Aff4
Aikawa, Masanori
Al Rasadi, Khalid
Amarenco, Pierre
Barter, Philip J.
Ceska, Richard
Corsini, Alberto
Després, Jean-Pierre
Duriez, Patrick
Eckel, Robert H.
Ezhov, Marat V.
Farnier, Michel
Ginsberg, Henry N.
Hermans, Michel P.
Ishibashi, Shun
Karpe, Fredrik
Kodama, Tatsuhiko
Koenig, WolfgangAff21, Aff22
Krempf, MichelAff23, Aff24, Aff25
Lim, Soo
Lorenzatti, Alberto J.Aff27, Aff28
McPherson, Ruth
Nuñez-Cortes, Jesus MillanAff30, Aff31, Aff32
Nordestgaard, Børge G.Aff33, Aff34, Aff35
Ogawa, Hisao
Packard, Chris J.
Plutzky, Jorge
Ponte-Negretti, Carlos I.
Pradhan, ArunaAff40, Aff41
Ray, Kausik K.
Reiner, Željko
Ridker, Paul M.
Ruscica, Massimiliano
Sadikot, Shaukat
Shimano, Hitoshi
Sritara, Piyamitr
Stock, Jane K.
Su, Ta-Chen
Susekov, Andrey V.
Tartar, André
Taskinen, Marja-Riitta
Tenenbaum, AlexanderAff52, Aff53
Tokgözoğlu, Lale S.
Tomlinson, Brian
Tybjærg-Hansen, AnneAff56, Aff57
Valensi, Paul
Vrablík, Michal
Wahli, WalterAff60, Aff61, Aff62
Watts, Gerald F.
Yamashita, ShizuyaAff64, Aff65, Aff66
Yokote, Koutaro
Zambon, Alberto
Libby, Peter
Źródło:: Cardiovascular Diabetology. 18(1)
: Czasopismo naukowe

Pełny tekst

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation